Role of Endothelial Function and Inflammation in Patients with Cardiovascular Risk Factors, with and without a History of Myocardial InfarctionŠebeštjen M.a · Šabovič M.a · Eržen B.a · Simčič S.b · Žegura B.a · Poredoš P.a · Keber I.a
aDepartment of Angiology, University Clinical Centre, Hospital of Internal Medicine, and bInstitute of Microbiology and Immunology, Medical Faculty, Ljubljana, Slovenia
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: Endothelial dysfunction and inflammation, in particular their lack of improvement after risk reduction, might better reflect advanced atherosclerosis than just the presence of risk factors. The aim of this study was to compare endothelial function and inflammatory parameters in high-risk patients who had no history of myocardial infarction and in patients in a stable phase after myocardial infarction. Methods: We compared endothelial function of the brachial artery, measured using high-resolution ultrasound, in 45 patients with hyperlipidaemia (Group 1), and in 45 patients in a stable period after myocardial infarction (Group 2). Forty-five healthy individuals served as a control group (Group 3). Results: Compared to patients with treated hyperlipidaemia, patients after myocardial infarction had lower values of total and LDL cholesterol (p = 0.015; 0.005) and homocysteine (p < 0.005), but marginally higher IL-6 levels (p = 0.1). Other measurements were comparable. However, flow-mediated dilation of the brachial artery was significantly diminished in patients after myocardial infarction (10.6 ± 3.0; 5.9 ± 4.0; 14.0 ± 1.9% for Groups 1–3; ANOVA p = 0.0001; respectively). Conclusions: We found that patients with previous myocardial infarction have substantially lower endothelial function and increased some inflammatory parameters than patients with a similar level of atherosclerotic risk profile but without clinically evident coronary artery disease.
© 2007 S. Karger AG, Basel
- Goode GK, Miller JP, Heagerty AM: Hyperlipidemia, hypertension and coronary artery disease. Lancet 1995;345:362–364.
- Stamler J, Stamler R, Neaton JD, Wentworth D, Daviglus ML, Garside D, Dyer AR, Liu K Greenland P: Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adults and middle-aged men and women. JAMA 1999;282:2012–2018.
- Schachinger V, Britten MB, Zeiher AM: Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000;101:1899–1906.
- Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclwiw MA, Nour KR, Quyyumi AA: Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002;106:653–658.
- Suwaidi JA, Hamasaki S, Higano ST, et al: Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000;101:948–954.
- MRFIT Research Group, Kuller LH, Tracy RP, Shaten J, Meilahn EN: Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol 1996;144:537–547.
- Ridker PM, Rifai N, Stampfer MJ, Hennekens CH: Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000;101:1767–1772.
- Welch GN, Lascalzo J: Homocysteine and atherothrombosis. N Engl J Med 1998;338:1042–1050.
- Chambers JC, Obeid OA, Kooner JS: Physiological increments in plasma homocysteine induce vascular endothelial dysfunction in normal human subjects. Arterioscler Thromb Vasc Biol 1999;19:2922–2927.
- Celermajer DS: Endothelial dysfunction: does it matter? Is it reversible? J Am Coll Cardiol 1997;30:325–333.
- Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P: Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986;315:1046–1051.
- Chowienczyk PJ, Watts GF, Cockcroft JR, Ritter JM: Impaired endothelium-dependent vasodilatation of forearm resistance vessels in hypercholesterolemia. Lancet 1992;340:1430–1432.
- Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE: Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990;323:22–27.
- Celermajer DS, Sorensen KE, Georgakopoulos D, Bull C, Thomas O, Robinson J, Deanfield JE: Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 1993;88:2149–2155.
- Clarkson P, Celermajer DS, Powe AJ, Donald AE, Henry RM, Deanfield JE: Endothelium-dependent dilation is impaired in young healthy subjects with a family history of premature coronary disease. Circulation 1997;96:3378–3383.
Friedwald WT, Levy RI, Frederickson DS: Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin Chem 1972;18:499–502.
- Roberts WL, Sedrick R, Moulton L, Spencer A, Rifai N: Evaluation of four automated high-sensitivity C-reactive protein methods: Implications for clinical and epidemiological applications. Clin Chem 2000;46:461–468.
- Okura Y, Takao M, Zhang B, Nakashima Y, Saku K: Cardiovascular risk factor profiles and endothelial function in coronary artery disease patients treated with statins. Hypertens Res 2004;27:723–729.
- Imamura A, Okumura K, Matsui H, Mizuno T, Ogawa Y, Imai H, Numaguchi Y, Sakai K, Murohara T: Endothelial nitric oxide synthase and methylenetetrahydrofolate reductase gene polymorphisms are associated with endothelial dysfunction in young, healthy men. Can J Cardiol 2004;20:1229–1234.
- Leeson CP, Hingorani AD, Mullen MJ, Jeerooburkhan N, Kattenhorn M, Cole TJ, Muller DP, Lucas A, Humphries SE, Deanfield JE: Glu298Asp endothelial nitric oxide synthase gene polymorphism interacts with environmental and dietary factors to influence endothelial function. Circ Res 2002;90:1153–1158.
- Steinberg HO, Bayazeed B, Hook G, Johnson A, Cronin J, Baron AD: Endothelial dyfunction is associated with cholesterol levels in the high normal range in humans. Circulation 1997;96:3287–3293.
- Jacobs M, Plane F, Bruckdorfer KR: Native and oxidized low-density lipoproteins have different inhibitory effects on endothelium-derived relaxing factor in the rabbit aorta. Br J Pharmacol 1990;100:21–26.
- Sakabe K, Fukuda N, Wakayama K, Nada T, Shinohara H, Tamura Y: Time course differences for statin-induced pleiotropic effects in hypercholesterolemic patients. Int J Cardiol 2004;94:111–117.
- Nawawi H, Osman NS, Annuar R, Khalid BA, Yusoff K: Soluble intercellular adhesion molecule-1 and interleukin-6 levels reflect endothelial dysfunction in patients with primary hypercholesterolaemia treated with atorvastatin. Atherosclerosis 2003;169:283–291.
- O’Driscoll G, Green D, Taylor RR: Simvastatin, an HMG-coenzyme A reductase inhibitor improves endothelial function within 1 month. Circulation 1997;95:1126–1131.
- Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T, Takeshita A: Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994;89:2519–2524.
- Laufs U, La Fata V, Plutzky J, Liao JK: Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998;97:1129–1135.
- Wagner AH, Kohler T, Ruckschloss U, Just I, Hecker M: Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000;20:61–69.
- Cockcroft JR, Chowienczyk PJ, Benjamin N, Ritter JM: Preserved endothelium-dependent vasodilatation in patients with essential hypertension. N Engl J Med 1994;330:1036–1040.
- Hornig B, Landmesser U, Kohler C, Ahlersmann D, Spiekermann S, Christoph A, Tatge H, Drexler H: Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation 2001;103:799–805.
- Ghiadoni L, Magagna A, Versari D, Kardasz I, Huang Y, Taddei S, Salvetti A: Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003;41:1281–1286.
- On YK, Kim CH, Oh BH, Lee MM, Park YB: Effects of angiotensin converting enzyme inhibitor and calcium antagonist on endothelial function in patients with essential hypertension. Hypertens Res 2002;25:365–371.
- Creager MA, Roddy M-A: Effect of captopril and enalapril on endothelial function in hypertensive patients. Hypertension 1994;24:499–505.
- Anderson TJ, Elstein E, Haber H, Charbonneau F: Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol 2000;35:60–66.
- Muhlen BV, Millgard J, Lind L: Effects of digoxin, furosemide, enalaprilat and metoprolol on endothelial function in young normotensive subjects. Clin Exp Pharmacol Physiol 2001;28:381–385.
- Ross R: Atherosclerosis – an inflammatory disease. N Engl J Med 1999;340:115–126.
- Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E: Elevation of tumor necrosis factor-α and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000;101:2149–2153.
- Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S, Zeiher AM: Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000;102:1000–1006.
- Takeda T, Hoshida S, Nishino M, Tanouchi J, Otsu K, Hori M: Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels. Atherosclerosis 2003;169:155–158.
- Di Napoli M, Papa F: Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration of C-reactive protein in patients with first-ever ischemic stroke. Stroke 2003;34:2922–2929.
- Ridker PM, Rifai N, Lowenthal SP: Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001;103:1191–1193.
- Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E; for the Cholesterol and Recurrent Events (CARE) Investigators: Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999;100:230–235.
- Strandberg TE, Vanhanen H, Tikkanen MJ: Associations between change in C-reactive protein and serum lipids during statin treatment. Ann Med 2000;32:579–583.
- Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, Szarek M, Libby P, Ganz P; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study Investigators: High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003;108:1560–1566.
- Maier W, Altwegg LA, Corti R, Gay S, Hersberger M, Maly FE, Sutsch G, Roffi M, Neidhart M, Eberli FR, Tanner FC, Gobbi S, von Eckardstein A, Luscher TF: Inflammatory markers at the site of ruptured plaque in acute myocardial infarction: locally increased interleukin-6 and serum amyloid A but decreased C-reactive protein. Circulation 2005; 111:1355–1361.
- Prasad A, Higano ST, Al Suwaidi J, Holmes DR Jr, Mathew V, Pumper G, Lennon RJ, Lerman A: Abnormal coronary microvascular endothelial function in humans with asymptomatic left ventricular dysfunction. Am Heart J 2003;146:549–554.
- Chauhan A, Mullins PA, Taylor G, Petch MC, Schofield PM: Both endothelium-dependent and endothelium-independent function is impaired in patients with angina pectoris and normal coronary angiograms. Eur Heart J 1997;18:60–68.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.